Clinical Trials on Nasopharyngeal Cancer

Total 51768 results

Sun Yat-sen University

Unknown

Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

Nasopharyngeal Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Baise and other collaborators

Unknown

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hong Kong Nasopharyngeal Cancer Study Group Limited
Sanofi; The University of Hong Kong; Merck Sharp & Dohme LLC; Roche Pharma AG

Completed

Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients

Nasopharyngeal Carcinoma

China
Chang Gung Memorial Hospital
TTY Biopharm

Unknown

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Taiwan
Ministry of Health, Malaysia

Completed

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Malaysia
Chinese University of Hong Kong
Queen Elizabeth Hospital, Hong Kong; Prince of Wales Hospital, Shatin, Hong...

Unknown

Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy

Nasopharyngeal Carcinoma | Radiotherapy

Hong Kong
Sun Yat-sen University
Eli Lilly and Company

Completed

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

Nasopharyngeal Neoplasms

China
Far Eastern Memorial Hospital
National Taiwan University Hospital

Unknown

Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

Taiwan
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy

Nasopharyngeal Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Chongqing University Cancer Hospital; Jiangxi Provincial Cancer Hospital; Shenzhen... and other collaborators

Recruiting

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Capecitabine | Radiotherapy | PD-1 Inhibitor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso

Recruiting

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, United States, Australia, Brazil, Canada
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Affiliated Cancer Hospital & Institute of Guangzhou... and other collaborators

Recruiting

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy

China, Singapore
Sun Yat-sen University
Wuhan University; Tongji Hospital; Hunan Province Tumor Hospital; Second Affiliated... and other collaborators

Recruiting

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma (IMRT)

Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Recruiting

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Sun Yat-sen University

Not yet recruiting

Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

Nasopharyngeal Carcinoma

China
Qilu Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 Inhibitors

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College; Affiliated...

Completed

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Nasopharyngeal Carcinoma

China
The University of Hong Kong

Withdrawn

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Nasopharyngeal Carcinoma
National Cancer Institute (NCI)

Terminated

Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

Nasopharyngeal Neoplasms

China
Johns Hopkins University
Janssen-Cilag Ltd.

Withdrawn

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, Singapore
Shanghai Proton and Heavy Ion Center

Terminated

Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Taichung Veterans General Hospital

Completed

The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients

Nasopharyngeal Carcinoma
Taichung Veterans General Hospital

Completed

Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Nasopharyngeal Carcinoma | Radiotherapy | EBV | NPC

Taiwan
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
Sun Yat-sen University

Unknown

The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients

Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital

Unknown

A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

Nasopharyngeal Neoplasms
National Taiwan University Hospital
National Health Research Institutes, Taiwan

Unknown

Molecular Mechanism of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Taiwan
Sun Yat-sen University

Not yet recruiting

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangxi Provincial Cancer Hospital

Recruiting

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangxi Provincial Cancer Hospital

Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal Carcinoma | Tumor Microenvironment | Pathologic Complete Response

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms

Clinical Trials on Nasopharyngeal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations